ClinicalTrials.gg
RecruitingNCT06953453Updated Sep 25, 2025

A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors

A Phase 1 interventional study of Inhaled Fentanyl Aerosol and Fentanyl Citrate Injection in Cancer, sponsored by Lee's Pharmaceutical Limited. Recruiting at 2 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Lee's Pharmaceutical Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.

Read the detailed description

Consenting patients who met inclusion and exclusion criteria were allowed to enter the study. The subjects will be randomly assigned (1:1) to receive an intravenous bolus (5 seconds) of 25μg fentanyl injection in the first cycle, and after a 2-week washout period, to receive a single dose of 25μg inhaled fentanyl aerosol through the Staccato delivery system in the second cycle; or to receive the same treatment in the opposite order.

02

Conditions studied

  • Cancer

Browse trials for

03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Lee's Pharmaceutical Limited is the lead sponsor of 74 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate, understand and sign the form before conducting the evaluation project;
  2. Male or female subjects, aged between 18 and 55, including 18 and 55 years old;
  3. Patients with malignant tumors diagnosed by histology or cytology;
  4. (BMI) is >21 kg/m2, but \<30 kg/m2;
  5. Have sufficient hematopoietic function and organ function within the last 14 days at random.

    1. The is ≥1.5×109/L (has not received colony stimulating factor treatment within 14 days before the examination);
    2. count ≥80×109/L (without transfusion of platelets or other platelet-increasing drugs within 14 days before the examination);
    3. ≥90g/L (without transfusion or treatment with other hemoglobin-increasing drugs within 7 days before the examination);
    4. rate (Ccr)≥30 ml/min, Cr≤2 times the value;
    5. (AST) and alanine aminotransferase (ALT) should be ≤2.5×ULN, and for subjects with liver , it should be ≤5×ULN; total should be ≤2 times the upper limit of normal value;
    6. Coagulation function ≤1.5 ULN;
    7. In a non-oxygen-absorbing state, the oxygen saturation (from a pulse oximeter) is SaO2>95%; pulmonary function shows /FVC>70% and FEV1 as a percentage of the predicted value is>80%;
  6. All patients must agree to take effective measures during the study and within one month after stopping treatment. Female patients of childbearing age must have a negative blood pregnancy test before administration;
  7. The performance status score is 0\~1 points;

Exclusion criteria

Exclusion Criteria:

  1. known or suspected allergy to opioids;
  2. used opioids within 14 days before the first administration, including but not limited to: codeine, dihydrocodeine, hydromorphone, oxycodone, methadone, morphine, fentanyl and pethidine (pethidine);
  3. plan to receive radiotherapy and / or systemic chemotherapy within 14 days before the first administration or during the study period (except for patients who receive or targeted drug maintenance therapy that is not a inhibitor / inducer and whose condition is stable);
  4. within 14 days before the first administration, the patient had received any monoamine oxidase (MAO) inhibitors (such as phenelzine, isocarbazine, chlorogiline, toloxadone, moclobemide, selegiline, rasagiline, etc.); Or have used CYP3A4 inhibitors (such as indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, nefazodone, ketoconazole, telithromycin, arepitan, erythromycin, fluconazole, grapefruit, verapamil, diltiazem, cimetidine, etc.) or CYP3A4 inducers (such as phenobarbital, carbamazepine, efavirenz, , modafinil, nevirapine, oxcarbazepine, phenytoin, pioglitazone, rifabutin, rifampicin);
  5. have participated in other clinical studies or received surgical treatment within 30 days before the screening period, or have surgery plans during the study period;
  6. subjects who smoked more than 10 cigarettes / day within 3 months before the screening period;
  7. subjects with a history of drug or alcohol dependence or abuse within 2 years before the screening period;
  8. subjects often eat food rich in xanthine (such as drinking more than 5 cups of coffee or food containing the same amount of xanthine every day);
  9. subjects with hypotension (systolic blood pressure \<90 mmHg, or diastolic blood pressure \<60 mmHg) or uncontrollable hypertension (refers to systolic blood pressure ≥ 160 mmHg, and / or diastolic blood pressure ≥ 100 mmHg after standard treatment);
  10. After antiviral treatment, >500 IU/mL or>2500 copies/mL; positive; Positive for antibodies; Or positive for syphilis antibodies;
  11. subjects with positive alcohol test or urine test at any visit of the study;
  12. subjects with an expected survival time of \<1 year;
  13. subjects with abnormalities during screening;
  14. subjects with a history of lung diseases (asthma, bronchitis, bronchospasm, emphysema, interstitial lung disease, pulmonary fibrosis, etc., excluding lung );
  15. subjects with history of unstable angina pectoris, syncope, coronary artery disease, myocardial infarction, congestive heart failure (CHF), stroke, (TIA) or major neurological diseases;
  16. presence of meningeal or requiring clinical intervention or malignancy related epilepsy;
  17. women of childbearing age or lactating women with positive blood and urine pregnancy tests;
  18. the investigator believes that any other situation that may affect the subject's provision of or compliance with the trial protocol, or the subject's participation in the trial may affect the trial results or their own safety.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Experimental:Inhaled fentanyl aerosol

    Subjects will be randomly assigned (1:1) to either drug sequence

    Drug: Inhaled Fentanyl Aerosol

  • Active comparator
    Active Comparator:Fentanyl Citrate Injection

    Subjects will be randomly assigned (1:1) to either drug sequence

    Drug: Fentanyl Citrate Injection

Interventions

  • DrugInhaled Fentanyl Aerosol

    The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg Fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg Fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.

  • The subjects will be randomly assigned (1:1) to either dosing sequence: in the first cycle, receive an intravenous bolus (5 seconds) of 25μg fentanyl injection, after at least a 2-week washout period, in the second cycle, receive a single dose of 25μg fentanyl aerosol inhaler through the Staccato delivery system; or receive the same treatment in the reverse order.

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak Concentration

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  2. Tmax

    Time to Maximum Concentration

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  3. Ke

    Terminal Elimination Rate

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  4. T1/2

    Terminal elimination half-life

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  5. CL/F

    Apparent Clearance (CL/F)

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  6. AUC_last

    Area Under the Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

  7. AUC_inf

    Area Under the Concentration-Time Curve from Time Zero to Infinity

    Time frame: Before administration (within 30 minutes), 15 seconds , 30 seconds, 45 seconds, 90 seconds, 3 minutes, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 18 hours after administration

Secondary outcomes

  1. Pupil diameter

    Measure the pupil diameter using a pupillometer.

    Time frame: Pupil measurements were taken before administration, and at 1, 2, 3, 5 , 10 , 30minutes , and 1, 2, 4, 8, 12 and 18hours after drug administration.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953453
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Sep 23, 2025
Primary completion
Jul 20, 2026 (estimated)
Completion
Aug 20, 2026 (estimated)
Last update
Sep 25, 2025

Study contacts

Haiyan Hu, doctor
Contact
xurill@163.com
+86 18930174575
Haiyan Hu, doctor
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion